Skip to main content
. 2021 Mar 6;5(7):bvab038. doi: 10.1210/jendso/bvab038

Table 1.

Demographics, serum TSH, and statin utilization in LT4-treated patients (site 1)

Group-0 Group-1 Group-2 Group-3 Group-4
have TSH 0.40 < TSH < 5.0 TSH < 0.40 TSH > 5.0
Number of patients 10 723 5112 3584 833 695
Sex
 Female 7562 (70%) 3607 (71%) 2538 (70%) 615 (73%) 454 (65%)
Race and Ethnicity
 White 6935 (64%) 2994 (59%) 2100 (58%) 544 (65%) 350 (50%)
 Not Hispanic or Latino 10 192 (95%) 4846 (95%) 3418 (95%) 781 (93%) 647 (93%)
Age at IE
 Mean (SD) (years) 59 (16) 58 (16) 59 (16) 55 (16) 58 (17)
 Median (min, max) (years) 61 (18, 92) 60 (18, 91) 61 (18, 91) 56 (19, 90) 59 (18, 91)
Statin utilization
 Before IE (%) 14.3 18.3 19.1 15.2 17.7
 After IE (%) 17.7 23.4 24.6 19.2 22.7
 Δ (percentage points) 3.4 5.1 5.5 4.0 5.0
McNemar’s chi-squared test with continuity correction
 chi-squared value 247 298 319 5.6 42
P value <.0001 <.0001 <.0001 .0183 <.0001
Serum TSH
 Median (mIU/L) (25th, 75th percentile) N/A 1.89 (0.71, 3.4) 1.97 (1.1,3.0) 0.11 (0.03, 0.25) 8.59 (6.1, 16)
TSH assessment (weeks after IE)
 Median (25th, 75th percentile) N/A 60 (32, 90) 61 (33, 90) 61 (37, 90) 56 (25, 90)
Started statin therapy (weeks after IE)
 Median (25th, 75th percentile) 49 (3, 109) 75 (18, 122) 76 (20, 121) 77 (3, 126) 70 (30, 120)

Group 0, all patients that met inclusion/exclusion criteria; Group 1, patients with serum TSH levels at or around the time therapy with statins was initiated; Group 2, patients with normal serum TSH after the IE; Group 3, patients with suppressed TSH after the IE; Group 4, patients with elevated TSH after the IE. In the control group, statin utilization increased by 1.7 percentage points on year- 2 and by 3.8 percentage points on year 3.

Abbreviations: IE, index encounter; LT4, levothyroxine; SD, standard deviation; N/A, not all values are available; TSH, thyrotropin.